We published a study in Nature Communications identifying connexin43 (Cx43) as a new therapeutic target in BRAF-mutant tumors such as melanoma, colorectal cancer, and breast cancer. Restoring Cx43 enhances the efficacy of BRAF/MEK inhibitors and can reverse drug resistance. The team also developed a patented mRNA-based therapy delivered through nanovesicles.
https://www.nature.com/articles/s41467-025-60971-3
You must be logged in to post a comment.